Journal ArticleDOI
Recombinant Immunotoxins: From Basic Research to Cancer Therapy
Ulrich Brinkmann,Ira Pastan +1 more
Reads0
Chats0
TLDR
This review describes immunotoxins, molecules that contain an antibody-derived antigen binding region (Fv) coupled to a bacterial toxin, most commonly Diphtheria toxin or Pseudomonas exotoxin.About:
This article is published in Methods.The article was published on 1995-10-01. It has received 31 citations till now. The article focuses on the topics: Diphtheria toxin & Immunotoxin.read more
Citations
More filters
Journal ArticleDOI
Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
TL;DR: The biochemical features of dsFvs in comparison with scFvs, the effect of disulfide stabilization on Fv binding and activity, and various applications of dSFvs and ds Fv-immunotoxins for tumor imaging and the treatment of solid tumors in animal models are discussed.
Journal ArticleDOI
Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors
Elizabeth Mansfield,P. Amlot,P. Amlot,Ira Pastan,Ira Pastan,David J. FitzGerald,David J. FitzGerald +6 more
TL;DR: These immunotoxins exhibited selective cytotoxic activity for CD22+ cells and antitumor activity in nude mouse models bearing human B-cell lymphomas and was dose responsive and was not evident when an irrelevant immunotoxin was administered on the same schedule.
Journal Article
Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
Yoram Reiter,Ira Pastan +1 more
TL;DR: A new type of recombinant Fv immunotoxin is developed in which the targeting variable domains of the Fv are stabilized by an interchain disulfide bond located in structurally conserved framework positions of the VH and VL domains, termeddisulfide-stabilized Fvs (dsFv) or dsFV immunotoxins.
Journal ArticleDOI
A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.
TL;DR: In this article, the authors used protein engineering to generate a stable bivalent Fv molecule of the anti-erbB2 monoclonal antibody e23, which is fused to a truncated form of Pseudomonas exotoxin to create a bivalent disulfide-stabilized, (dsFv) 2, immunotoxin.
Book ChapterDOI
Recombinant immunotoxins in targeted cancer cell therapy.
TL;DR: The results demonstrate that recombinant immunotoxins can be developed into a separate modality of cancer treatment with the basic rationale of specifically targeting cancer cells on the basis of their unique surface markers.
Related Papers (5)
A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies
Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes
F W Studier,B A Moffatt +1 more